Xcout Intel
Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Subscribe to see Bellerophon Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bellerophon Therapeutics, Inc. at a glance
Bellerophon Therapeutics, Inc. is a biotech company headquartered in United States. It has raised at least $25M across the 2 funding rounds on record. Its most recent funding round raised $23.4M in September 2017. Xcout tracks 13 named people at Bellerophon Therapeutics, Inc., including Leigh-Anne Claase (Chief Executive Officer).
Bellerophon Therapeutics, Inc. leadership
- Leigh-Anne ClaaseChief Executive Officer
- Con HoraitisExecutive Director Technology
- Emma BarkerExecutive Director Sales and Marketing
- Emma JuniperExecutive Director Publishing
- Sonia KokkalosExecutive Director - People & Corporate Services
- Leanne RussellCompany Secretary
7 more named people on record for Bellerophon Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Bellerophon Therapeutics, Inc. funding rounds
At least $25M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $23.4M | — | |
| SEC Form D filing | $1.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Bellerophon Therapeutics, Inc. competitors
A few of Bellerophon Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
AeroRx Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic obstructive pulmonary disease (COPD).
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Pahr Therapeutics, Inc. is a biotechnology company focused on developing new treatments for pulmonary arterial hypertension (PAH). The company recently raised $14 million in seed funding to support its therapeutic development efforts.
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
AllRock Bio is a clinical-stage biotechnology company headquartered in Natick, Massachusetts, dedicated to developing transformative therapies for cardiopulmonary and fibrotic conditions.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Get Bellerophon Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Bellerophon Therapeutics, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access